AI-Powered Test Automation: Redefining Speed, Safety, and Efficiency in Clinical Trials

Automation in clinical trials has been a topic of conversation for years, yet the reality of widespread adoption has remained stubbornly out of reach. While areas like pharmacovigilance have embraced NLP to screen adverse event reports, and regulatory operations have leveraged RPA for protocol amendments, the clinical data management process has lagged behind. The pandemic, combined with the rapid rise of generative AI, has brought renewed urgency to the question: Is now finally the moment for clinical trial data automation to transform how we run studies?

At the Indegene Digital Summit 2025, Dr. Nasrin Bidarakund engaged in a candid conversation with Greg Ambra, a seasoned life sciences executive and CEO of a multinational CRO, to explore what it genuinely takes to integrate AI-powered test automation into clinical data workflows. Their discussion offered a grounded perspective on the most pressing barriers to adoption and the transformative opportunities that await organizations ready to make the leap.

For an industry defined by precision, clinical data management has been surprisingly slow to embrace innovation, and the reasons, as Greg outlined, are both structural and cultural.

Regulatory conservatism plays a central role. Operating in one of the most tightly regulated environments in the world, organizations are understandably reluctant to adopt unproven technologies when patient safety and regulatory integrity are on the line. Most prefer to let solutions mature before committing to implementation. The variability of clinical trials adds another layer of complexity. Oncology programs, rare disease studies, and medical device trials each carry distinct data structures, making it exceptionally difficult to standardize automated processes across studies.

Established practice also exerts a powerful pull. Data management professionals are trained within well-defined methodological and regulatory frameworks and transitioning experienced teams away from these, even incrementally, generates friction that is not easily overcome. Although some lightweight EDC systems have begun incorporating automation, these solutions rarely meet the demands of large, complex trials. Adoption remains especially limited in oncology and rare disease settings, where the margin for error is virtually nonexistent.

One of the session's most compelling insights centered on how automation in clinical trials stands to fundamentally reshape, not merely improve the sponsor-CRO relationship. Greg described the impact as inherently dichotomous. In the near term, sponsors will grow increasingly aware of the cost savings and timeline efficiencies that automation enables and will start expecting these capabilities from their CRO partners. This will place considerable pressure on CROs to innovate and to do so quickly. Yet that pressure, while challenging, is far from counterproductive. It will catalyze investment in new capabilities and push organizations to reimagine their operating models from the ground up.

The longer-term opportunity, however, is where the real transformation lies. Unlocking the full potential of automation will require sponsors and CROs to move well beyond transactional partnerships. True value will emerge through genuine integration, shared data ecosystems, aligned workflows, and co-designed automation strategies built to serve the entire trial lifecycle. As both speakers acknowledged, this kind of change will not come easily. But for organizations willing to embrace it, deeper integration may well prove to be the defining opportunity of this era.

When pressed on where AI-powered test automation offers the most compelling ROI today, Greg's answer was immediate: User Acceptance Testing (UAT) for EDC builds. UAT; the process of writing, executing, and documenting test scripts to verify that an EDC system functions correctly before a study goes live, ranks among the most manual, time-consuming tasks in clinical data management. Teams must methodically validate every data point, dropdown, checkbox, and edit check for accuracy. Mid-study amendments compound this burden further, triggering delays that cascade across trial timelines.

What makes UAT the ideal entry point for automation is the convergence of high manual effort and clear, verifiable output. Unlike many AI-driven processes that feel opaque, automated UAT generates transparent, auditable results that both sponsors and regulators can scrutinize with confidence. With well-defined inputs, outputs, and internal controls, it represents exactly the kind of environment where automation delivers maximum, demonstrable value.

Beyond UAT, Greg pointed to a broader pipeline of automation opportunities gaining real momentum — from SDTM conversion and query management to medical coding and EDC builds — each offering meaningful potential to compress timelines and reduce manual overhead.

As automation moves deeper into clinical workflows, regulatory compliance is not a secondary consideration — it is the foundation every implementation must be built upon. The question facing CROs and sponsors is not whether to automate, but how to do so without compromising their regulatory standing.

Greg's prescription was pragmatic: start small, build trust, and iterate. Pilot programs contain risk by enabling teams to test new processes at a manageable scale, incorporate stakeholder feedback early, and course-correct before any large-scale rollout. The iterative cycle — try, learn, refine, repeat — generates invaluable real-world experience without exposing the organization to the consequences of an enterprise-wide failure.

Underpinning all of this is an unwavering commitment to documentation. In clinical trials, if it is not documented, it did not happen. Every automated workflow introduced into a clinical environment must be built with transparency and explainability at its core — ready to withstand internal QA audits and FDA inspections alike. Regulators need to see not just what was done, but why the process was sound. The goal is not automation for its own sake. It is automation that is fully audit-ready from day one.

No conversation about automation is complete without confronting the workforce question head-on: what happens to the people who currently perform these tasks?

Greg's perspective was both clear-eyed and optimistic. Full automation of clinical data management is not a near-term reality, the complexity and study-specific nuance of the work make it implausible. What is already underway, however, is a fundamental elevation of the data manager's role.

Historically, data managers have operated in silos, focused on rote, repetitive tasks; writing and answering queries, building EDC databases, executing test scripts. AI-powered automation on the front end liberates these professionals from high-volume manual work, opening space for more meaningful contributions in protocol development, data quality strategy, and cross-functional decision-making.

This evolution suits data managers well. Many bring programming and logic-oriented backgrounds that translate naturally into understanding, implementing, and overseeing AI-driven workflows. Expanding into AI, ML, and NLP is a natural progression — and it offers something the field has long deserved: a genuine seat at the strategic table.

Despite its clear promise, AI-powered test automation in clinical data management has yet to reach critical mass. Two forces are most likely to act as catalysts: executive leadership within organizations and sustained pressure from sponsors.

Data managers, by training and temperament, are cautious — conditioned to follow established procedures and rarely empowered to unilaterally introduce new methodologies. When organizational leadership clears the path and sponsors push for faster timelines and leaner budgets, adoption shifts from optional to imperative.

The broader industry context reinforces this momentum. Generative AI and automation are no longer niche topics — they are board-level conversations. As real-world evidence of ROI continues to accumulate, the case for adoption becomes increasingly difficult to dismiss or defer.

Legacy CROs, constructed over decades around vertical, siloed processes, are structurally ill-equipped for rapid transformation. Smaller, more agile organizations — and digital-first CROs like Indegene — are far better positioned to serve as proving grounds for automation in clinical trials. They can experiment without bureaucratic drag, fail fast, refine quickly, and generate the genuine learning that larger players eventually absorb and scale.

Indegene's unique positioning — grounded in deep life sciences domain expertise while committed to challenging industry conventions — is precisely where transformational change takes root. As Greg noted, digital CROs like Indegene represent exactly the kind of environment where new implementations move from concept to reality.

Five years from now, clinical data management will look different — but not unrecognizable. The future Greg envisions is not a fully automated, push-button operation. It is a thoughtful human-AI partnership, where automation absorbs the high-volume, repetitive tasks — UAT, SDTM conversion, query management, medical coding — while skilled data managers apply judgment, clinical context, and regulatory expertise to the decisions that truly matter.

The message from the Indegene Digital Summit 2025 is unambiguous: AI-powered automation is not about replacing human expertise — it is about amplifying it. For organizations ready to move from hesitation to intentional action, the tools, the knowledge, and the opportunity are already within reach.